A study showed that the use of osimertinib immediately after nivolumab is associated with higher incidence of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboring EGFR mutation acquired T790M resistance (171). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.